Half Year 2026 EBOS Group Ltd Earnings Call Transcript
Key Points
- Ebos Group Ltd (ASX:EBO) reaffirmed its FY26 EBITDA guidance, indicating confidence in meeting financial targets.
- Healthcare EBITDA increased by 1.3% to $254 million, driven by strong revenue growth and disciplined cost management.
- Animal Care EBITDA grew 15.1% to $68 million, reflecting strong branded performance and successful new product innovation.
- The DC renewal program is progressing well, with the largest site, Kemps Creek, now fully operational and performing as expected.
- The company maintained a strong balance sheet with leverage within the target range, and expects leverage to reduce in FY27 as CapEx decreases by about 30%.
- Underlying NPAT was slightly down to $125 million due to the DC capital renewal program and timing factors.
- The company faced ongoing competition in the community pharmacy sector, impacting core margins.
- Net finance costs increased to $58 million, reflecting higher Australian cash rates and additional funding costs.
- The transition activities related to the DC renewal program impacted productivity and operating costs.
- The company expects interest and D&A growth to remain elevated in the second half due to the capital renewal cycle.
Thank you for standing by, and welcome to the EBOS Group Limited fiscal year '26 half year results conference call. (Operator Instructions) I must advise you that this conference is being recorded today, the 25th of February 2026. I would now like to hand the call over to your first speaker today, Mr. Martin Krauskopf, Chief Strategy and Corporate Development Officer, EBOS Group. Please go ahead, Martin.
Good morning, everyone, and thank you for your attendance today. My name is Martin Krauskopf, Chief Strategy and Corporate Development Officer. I'm joined today by Adam Hall, our Group CEO; and Alistair Gray, our Group CFO. Before commencing, I'd like to draw your attention to the disclaimer on Page 2 of the presentation. The results are expressed in Australian dollars, unless otherwise noted, and the presentation refers to both statutory and underlying results.
The commentary this morning is predominantly based on our underlying results, and a reconciliation is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
